Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://jh.elmerpub.com

Original Article

Volume 15, Number 5, October 2026, pages 236-247

Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared to Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute Myeloid Leukemia With t(8;21) (q22;q22.1)

Figures

↓  Figure 1. Overall survival for all patients.
Figure 1.
↓  Figure 2. Disease-free survival for patients achieving remission.
Figure 2.
↓  Figure 3. Overall survival difference by white blood cell count > or < 20.
Figure 3.
↓  Figure 4. Overall survival by era of treatment, before or after 2005.
Figure 4.
↓  Figure 5. Overall survival by presence or absence of extramedullary disease.
Figure 5.
↓  Figure 6. Consort diagram of treated patients. PRT: post-remission therapy.
Figure 6.
↓  Figure 7. Overall survival of patients by post-remission therapy arms.
Figure 7.
↓  Figure 8. Cumulative incidence of relapse by post-remission therapy, hematopoietic cell transplantation vs. chemotherapy.
Figure 8.

Tables

↓  Table 1. Patient Characteristics
 
CategoryVariableValue (percentage/range)
DemographicsSexFemale 28 (47.46%) Male 31 (52.54%)
Median age, years (range)23 (14–57)
Age under 40 years50 (84%)
Laboratory and disease characteristicsWBC count, median (range)10 (1.06–104)
WBC count > 2018/58 (31%)
Platelet count, median (range)30 (5–477)
Additional cytogenetic abnormalities37/58 (63.7%)
del(9q)6/58 (10%)
Loss of sex chromosome18/57 (14%)
Extramedullary disease11/58 (19%)
Molecular and immunophenotypic featuresKIT mutation positive3/21 (14%)
CD36 positive26/40 (65%)
FLT3 mutation1/14 (7%)
CD19 positive36/45 (80%)
Induction treatmentICE39 (66%)
3+716 (27%)
FA/FLAG-IDA2 (3%)
ARAC1 (2%)
Other2 (3%)

 

↓  Table 2. Baseline Characteristics of the 49 Patients Receiving Adequate Post-Remission Therapy, by Treatment Arm
 
CharacteristicAutoHCT (n = 15)AlloHCT (n = 20)Chemotherapy (n = 14)P-value*
*P-values from Kruskal–Wallis test (age) or chi-square test (categorical variables) across the three post-remission therapy arms. alloHCT: allogeneic HCT; autoHCT: autologous transplant; WBC: white blood cell count.
Age, median (range), years31 (16–57)20.5 (14–45)24 (14–56)0.029
WBC > 20 × 109/L4/15 (27%)5/19 (26%)5/14 (36%)0.81
Extramedullary disease4/15 (27%)3/20 (15%)4/14 (29%)0.58
CD56 positive10/12 (83%)7/11 (64%)6/12 (50%)0.22
Additional cytogenetic abnormality9/14 (64%)14/20 (70%)6/14 (43%)0.26
Del(9q)3/14 (21%)2/20 (10%)0/14 (0%)0.18
Male sex6/15 (40%)12/20 (60%)6/14 (43%)0.44

 

↓  Table 3. CIR and NRM by Post-Remission Therapy
 
PRT armCIRNRM
ProbabilityStandard error95% LLC95% ULCP-valueProbabilityStandard error95% LLC95% ULCP-value
CIR: cumulative incidence of relapse; LLC: lower limit of confidence; PRT: post-remission therapy; ULC: upper limit of confidence.
HCT0.2821.875148.00233.750.0440.120.0580.00710.2320.16
CHEMO0.6415.2417.9277.690000
AutoHCT0.3334.361111.74246.4420000
AlloHCT0.1519.130105.29180.280.1090.20.090.02360.3760.19
CHEMO0.6415.24917.9277.6950000